Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Boehringer Ingelheim
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01751776
First received: December 14, 2012
Last updated: October 14, 2014
Last verified: October 2014

December 14, 2012
October 14, 2014
December 2012
April 2015   (final data collection date for primary outcome measure)
  • Primary PK endpoint (Part 1): Cmax (after first and 4th dose) [ Time Frame: up to Day 64 post-treatment ] [ Designated as safety issue: No ]
  • Primary PK endpoint (Part 1): AUC 0-infinity (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinite) [ Time Frame: Up to Day 64 post-treatment ] [ Designated as safety issue: No ]
  • Primary PK endpoint (Part 1): AUC t,4 (Area under the concentration-time curve of the analyte in plasma after the 4th dose over a uniform dosing interval t) after the first and 4th dose) [ Time Frame: Up to Day 64 post-treatment ] [ Designated as safety issue: No ]
  • Number of subjects with drug related Adverse Events (Part 1). [ Time Frame: Up to Day 64 post-treatment ] [ Designated as safety issue: No ]
  • ACR20 (American College of Rheumatology) response rate at week 12 (day 85) from the initiation of study treatment (Part 2) [ Time Frame: week 12 ] [ Designated as safety issue: No ]
  • Percentage of patients with a decrease in DAS28 4v-CRP of >1.2 at week 12 (day 85) compared to baseline [ Time Frame: baseline and week 12 ] [ Designated as safety issue: No ]
  • ACR50 and 70 response rates at week 12 (day 85) [ Time Frame: week 12 ] [ Designated as safety issue: No ]
  • ACR20 (American College of Rheumatology) response rate at week 12 (day 85) from the initiation of study treatment [ Time Frame: week 12 ] [ Designated as safety issue: No ]
  • EULAR (European League Against Rheumatism) response criteria measured as the disease activity score with four variables including c-reactive protein (DAS28 4v-CRP) at week 12 (day 85) [ Time Frame: week 12 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01751776 on ClinicalTrials.gov Archive Site
  • ACR50 and 70 response rates at week 12 (day 85) (Part 2) [ Time Frame: week 12 ] [ Designated as safety issue: No ]
  • EULAR (European League Against Rheumatism) response criteria (DAS28 4v-CRP and DAS 28 4v-ESR) at week 12 (day 85) (Part 2) [ Time Frame: week 12 ] [ Designated as safety issue: No ]
  • Percentage of patients with a decrease in DAS28 4v-CRP of >1.2 at week 12 (day 85) compared to baseline (Part 2) [ Time Frame: baseline and week 12 ] [ Designated as safety issue: No ]
  • Change in DAS28-4v at week 12 (day 85) compared to baseline (Part 2) [ Time Frame: baseline and week 12 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Not Provided
 
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

To evaluate the safety and tolerability of multiple doses of BI 655064 administered subcutaneously in healthy volunteers (HVs) and in rheumatoid arthritis (RA) patients. To explore the pharmacokinetic (PK) and pharmacodynamic (PD) parameters of multiple doses of BI 655064 in healthy volunteers (HVs) and rheumatoid arthritis (RA) patients. To assess clinical effect of BI 655064 in RA patients with prior inadequate response to methotrexate (MTX) after 12 weeks of treatment

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
  • Arthritis, Rheumatoid
  • Healthy
  • Drug: BI 655064 medium dose
    Medium dose
  • Drug: BI 655064 high dose
    High dose
  • Drug: Placebo
    Placebo
  • Drug: BI 655064 low dose
    Low dose
  • Experimental: BI 655064 Part 1
    3 different doses plus placebo in healthy volunteers
    Interventions:
    • Drug: BI 655064 medium dose
    • Drug: BI 655064 high dose
    • Drug: Placebo
    • Drug: BI 655064 low dose
  • Experimental: BI 655064 Part 2
    2 different doses plus placebo in rheumatoid arthritis patients
    Interventions:
    • Drug: BI 655064 high dose
    • Drug: Placebo
    • Drug: BI 655064 medium dose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
106
June 2015
April 2015   (final data collection date for primary outcome measure)

Inclusion criteria:

Part 1 (phase Ib) (HVs):

  1. Healthy males and females according to the investigators assessment, as based on the following criteria: a complete medical history including a physical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests
  2. Age >= 18 and <= 60 years
  3. Body Mass Index >= 18.5 and <= 29.9 kg/m2
  4. Signed and dated written informed consent prior to admission to the study in accordance with GCP and the local legislation
  5. Female subjects who meet any of the following criteria from at least 30 days before the first study drug administration and until 30 days after trial completion:

    • using adequate contraception, e.g. any of the following methods plus condom: implants, injectables, combined oral contraceptives, intrauterine device (IUD)
    • sexually abstinent
    • have a vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
    • surgically sterilised (including hysterectomy)
    • postmenopausal defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of follicle stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)

Part 2 (phase IIa) (RA Patients):

  1. Age >= 18 and <= 70 years
  2. Patients classified as having RA according to the 1987 ACR Classification Criteria
  3. Inadequate clinical response to methotrexate monotherapy defined as moderate/high active disease after oral or s.c. MTX treatment given continuously for at least 3 months and for the last 6 weeks before screening at a stable weekly dose =15mg. For patients who do not tolerate the minimum weekly dose of at least 15 mg due to side effects, a stable weekly dose as low as 7.5 mg is also permitted.
  4. DAS28 4v-CRP >= 3.5 with >= 6 tender and >= 6 swollen joints out of 68/66 joint count at screening and confirmed by >= 6 tender and >= 6 swollen joints out of 68/66 joint count only at randomisation visit (Visit 2)
  5. Serum CRP level >= 0.8 mg/dL or ESR >= 28 mm/1h at screening
  6. Anti-CCP2 or Rheumatoid Factor positivity as per the limits of used assay at screening
  7. Female patients who meet any of the following criteria from at least 30 days before the first study drug administration and until at least 6 months after last dose of MTX taken in the current trial:

    using adequate contraception, e.g. any of the following methods plus condom: implants, injectables, combined oral contraceptives, intrauterine device (IUD)

    • sexually abstinent
    • have a vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
    • surgically sterilised (including hysterectomy)
    • postmenopausal defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of follicle stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)

    OR

    Male patients who:

    • are documented to be sterile or consistently and correctly use a condom while their female partners (if of childbearing potential) agree to use any of the following adequate contraception methods: implants, injectables, combined oral contraceptives, intrauterine device (IUD) from the date of screening until at least 6 months after the last dose of MTX taken in the current trial
    • don¿t donate any sperm sample for procreation purposes, from the date of screening until at least 6 months after last dose of MTX taken in the current trial.
  8. Signed and dated written informed consent prior to admission to the study in accordance with GCP and local legislation

Exclusion criteria:

Part 1 (phase Ib in HVs):

  1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal and judged clinically relevant by the investigator
  2. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  3. Any evidence of a concomitant disease judged clinically relevant by the investigator
  4. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  5. Diseases of the central nervous system (such as epilepsy), other neurological disorders or psychiatric disorders
  6. History of relevant orthostatic hypotension, fainting spells, or blackouts
  7. History of relevant allergy/hypersensitivity (including allergy to the trial medication or its excipients)

9. Within 10 days prior to administration of trial medication, use of drugs that might reasonably influence the results of the trial 12. Alcohol abuse (consumption of more than 140 g/week in females and 210 g/week in males) 13. Drug abuse or positive drug screen 17. Chronic or relevant acute infections, including but not limited to HIV, Hepatitis B and C and tuberculosis (including a history of clinical TB and/or a positive QuantiFERON TB-Gold test) 18. Subject is assessed by the investigator as unsuitable for inclusion e.g. considered not able to understand and comply with study requirements or has a condition that would not allow safe participation in the study 19. Positive pregnancy test, pregnancy or plans to become pregnant within 30 days after study completion 20. Lactation

Further exclusion criteria applicable for part 1 only are given in the CTP.

Part 2 (phase IIa in RA patients):

Part 1 (phase Ib) exclusion criteria 7, 9, 12, 13 and 17-20 plus:

  1. Current or previous use of more than two anti-TNF biologic drugs or use of other biologic agent targeting any other approved mechanism (any biologic drug with mechanism of action other than direct anti-TNF blockade, (e.g. CTLA4, anti-IL6, or anti CD-20) or new oral compounds targeting any other approved mechanism (e.g. JAK inhibitors) for treating RA.
  2. Current or previous participation in a clinical trial testing an investigational drug for RA within 3 months prior to screening or within 5 half-lives of the investigational drug, whichever is longer , except of previous participation in trials testing NSAIDs, corticosteroids, analgesics or patients documented as receiving placebo in previous RA trials.
  3. DAS28 < 3.2 in at least 2 occasions during the last 6 months before screening
  4. RA patients with severe disability (functional class IV) or with confirmed severe systemic manifestations e.g. known amyloidosis, Felty´s syndrome, lymphoproliferative disorders, rheumatoid vasculitis
  5. Treatment with any standard DMARD except MTX (including but not limited to sulfasalazine, leflunomide, hydroxychloroquine, D-penicillamine
  6. Impaired hepatic function, defined as serum AST/ALT, bilirubin or alkaline phosphatase levels > 2 x ULN
  7. Impaired renal function defined as calculated creatinine clearance < 50ml/min
  8. Pre-existing blood dyscrasias e.g. bone marrow hypoplasia, significant anaemia, leucopenia or thrombocytopenia
  9. Hypersensitivity to MTX or any of its excipients
  10. Previous intolerance to MTX as the main cause for stopping treatment (instead of lack of efficacy)
  11. Any active or suspected malignancy or history of documented malignancy within the last 5 years before screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
Both
18 Years to 70 Years
Yes
Contact: Boehringer Ingelheim Call Center 1-800-243-0127 clintriage.rdg@boehringer-ingelheim.com
New Zealand,   Germany,   Spain,   Poland,   Czech Republic,   Netherlands,   Romania
 
NCT01751776
1293.2, 2012-004090-16
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP